Novel blood test that helps neurologists objectively manage patients with MS.
Minpunten
New leadership puts their goal of receiving next level funding/revenue over patient care. Drove cost of the test up by 500% for MS patients that already had difficulty affording the test. Tarnished relationships with providers and their staff.